Solubilized extracellular matrix from brain and urinary bladder elicits distinct functional and phenotypic responses in macrophages

Biomaterials

Volumn 46, Issue , 2015, Pages 131-140

  Meng, Fan Wei ^a   Slivka, Peter F ^a   Dearth, Christopher L ^a,b,c   Badylak, Stephen F ^a,b,d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d University of Pittsburgh   (United States)

Author keywords

Cyclooxygenase; Extracellular matrix; Hyaluronic acid; Hydrogel; Macrophage

Indexed keywords

HISTOLOGY; HYALURONIC ACID; HYDROGELS; ORGANIC ACIDS; TISSUE;

CYCLOOXYGENASES; EXTRACELLULAR MATRICES; MACROPHAGE PHENOTYPES; MOLECULAR COMPOSITIONS; PHENOTYPIC RESPONSE; SMALL INTESTINE; THERAPEUTIC POTENTIALS; TISSUE RECONSTRUCTION;

MACROPHAGES;

ARGINASE; HYALURONIC ACID; HYALURONIDASE; NITRIC OXIDE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; TUMOR NECROSIS FACTOR ALPHA; HYALURONOGLUCOSAMINIDASE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ARTICLE; BLADDER; BRAIN; BRAIN FUNCTION; CONTROLLED STUDY; ELECTROPHORESIS; ENZYME ACTIVITY; ESOPHAGUS; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; HOMEOSTASIS; HYDROGEL; MACROPHAGE; MACROPHAGE FUNCTION; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; RAT; UPREGULATION; ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; METABOLISM; MOUSE; PIG; SECRETION (PROCESS); SOLUBILITY;

ANIMALS; ARGINASE; BRAIN; CELL DIFFERENTIATION; CELLS, CULTURED; DINOPROSTONE; EXTRACELLULAR MATRIX; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; MACROPHAGES; MICE; NITRIC OXIDE; PHAGOCYTOSIS; PHENOTYPE; SOLUBILITY; SUS SCROFA; TUMOR NECROSIS FACTOR-ALPHA; URINARY BLADDER;

EID: 84922811355     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.12.044     Document Type: Article

References (84)

1. Maharjan A.S., Pilling D., Gomer R.H. High and low molecular weight hyaluronic acid differentially regulate human fibrocyte differentiation. PLoS One 2011, 6:e26078.
2. Valentin J.E., Turner N.J., Gilbert T.W., Badylak S.F. Functional skeletal muscle formation with a biologic scaffold. Biomaterials 2010, 31:7475-7484.
3. Agrawal V., Brown B.N., Beattie A.J., Gilbert T.W., Badylak S.F. Evidence of innervation following extracellular matrix scaffold-mediated remodelling of muscular tissues. JTissue Eng Regen Med 2009, 3:590-600.
4. Brown B.N., Badylak S.F. Expanded applications, shifting paradigms and an improved understanding of host-biomaterial interactions. Acta Biomater 2012, 9:4948-4955.
5. Marcal H, Ahmed T, Badylak SF, Tottey S, Foster LJ. A comprehensive protein expression profile of extracellular matrix biomaterial derived from porcine urinary bladder. Regen Med 7:159-166.
6. Tidball J.G. Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol 2005, 288:R345-R353.
7. Tidball J.G. Mechanisms of muscle injury, repair, and regeneration. Compr Physiol 2011, 1:2029-2062.
8. Brown B.N., Londono R., Tottey S., Zhang L., Kukla K.A., Wolf M.T., et al. Macrophage phenotype as a predictor of constructive remodeling following the implantation of biologically derived surgical mesh materials. Acta Biomater 2012, 8:978-987.
9. Brown B.N., Valentin J.E., Stewart-Akers A.M., McCabe G.P., Badylak S.F. Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component. Biomaterials 2009, 30:1482-1491.
10. Valentin J.E., Stewart-Akers A.M., Gilbert T.W., Badylak S.F. Macrophage participation in the degradation and remodeling of extracellular matrix scaffolds. Tissue Eng A 2009, 15:1687-1694.
11. Freytes D.O., Martin J., Velankar S.S., Lee A.S., Badylak S.F. Preparation and rheological characterization of a gel form of the porcine urinary bladder matrix. Biomaterials 2008, 29:1630-1637.
12. Medberry C.J., Crapo P.M., Siu B.F., Carruthers C.A., Wolf M.T., Nagarkar S.P., et al. Hydrogels derived from central nervous system extracellular matrix. Biomaterials 2012, 34:1033-1040.
13. Bible E., Dell'Acqua F., Solanky B., Balducci A., Crapo P.M., Badylak S.F., et al. Non-invasive imaging of transplanted human neural stem cells and ECM scaffold remodeling in the stroke-damaged rat brain by (19)F- and diffusion-MRI. Biomaterials 2012, 33:2858-2871.
14. Modo M., Ambrosio F., Friedlander R.M., Badylak S.F., Wechsler L.R. Bioengineering solutions for neural repair and recovery in stroke. Curr Opin Neurol 2013, 26:626-631.
15. Seif-Naraghi S.B., Singelyn J.M., Salvatore M.A., Osborn K.G., Wang J.J., Sampat U., et al. Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction. Sci Transl Med 2013, 5:173ra25.
16. Slivka P.F., Dearth C.L., Keane T.J., Meng F.W., Riggio R.T., Reing J., et al. Fractionation of an ECM hydrogel into structural and soluble components reveals distinctive roles in regulating macrophage behavior. Biomater Sci 2014, 2:1521-1534.
17. Sicari B.M., Dziki J.L., Siu B.F., Medberry C.J., Dearth C.L., Badylak S.F. The promotion of a constructive macrophage phenotype by solubilized extracellular matrix. Biomaterials 2014, 35:8605-8612.
18. Mantovani A., Sica A., Locati M. Macrophage polarization comes of age. Immunity 2005, 23:344-346.
19. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677-686.
20. Lawrence T., Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol 2011, 11:750-761.
21. Mantovani A., Locati M. Orchestration of macrophage polarization. Blood 2009, 114:3135-3136.
22. Novak M.L., Koh T.J. Macrophage phenotypes during tissue repair. JLeukoc Biol 2013, 93:875-881.
23. Zhang L., Zhang F., Weng Z., Brown B., Yan H., Ma X., et al. Effect of an inductive hydrogel composed of urinary bladder matrix upon functional recovery following traumatic brain injury. Tissue Eng A 2013, 19:1909-1918.
24. van Amerongen M.J., Harmsen M.C., van Rooijen N., Petersen A.H., van Luyn M.J.A. Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am J Pathol 2007, 170:818-829.
25. Maruyama K., Asai J., Ii M., Thorne T., Losordo D.W., D'Amore P.A. Decreased macrophage number and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic wound healing. Am J Pathol 2007, 170:1178-1191.
26. Villalta S.A., Nguyen H.X., Deng B., Gotoh T., Tidball J.G. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet 2009, 18:482-496.
27. Vorotnikova E., McIntosh D., Dewilde A., Zhang J., Reing J.E., Zhang L., et al. Extracellular matrix-derived products modulate endothelial and progenitor cell migration and proliferation invitro and stimulate regenerative healing invivo. Matrix Biol 2010, 29:690-700.
28. Reing J., Zhang L., Myers-Irvin J., Cordero K., Freytes D., Heber-Katz E., et al. Degradation products of extracellular matrix affect cell migration and proliferation. Tissue Eng A 2009, 15:605-614.
29. Zhong C., Chrzanowska-Wodnicka M., Brown J., Shaub A., Belkin A.M., Burridge K. Rho-mediated contractility exposes a cryptic site in fibronectin and induces fibronectin matrix assembly. JCell Biol 1998, 141:539-551.
30. Ingham K.C., Brew S.A., Migliorini M. Type I collagen contains at least 14 cryptic fibronectin binding sites of similar affinity. Arch Biochem Biophys 2002, 407:217-223.
31. Slivka P.F., Dearth C.L., Keane T.J., Meng F.W., Medberry C., Riggio R.T., et al. Fractionation of an ECM hydrogel into structural and soluble components reveals distinctive roles in regulating macrophage behavior. Biomater Sci 2014, 2:1521-1534.
32. Sicari B.M., Rubin J.P., Dearth C.L., Wolf M.T., Ambrosio F., Boninger M., et al. An acellular biologic scaffold promotes skeletal muscle formation in mice and humans with volumetric muscle loss. Sci Transl Med 2014, 6:234ra58.
33. Ruoslahti E. Brain extracellular matrix. Glycobiology 1996, 6:489-492.
34. Lau L.W., Cua R., Keough M.B., Haylock-Jacobs S., Yong V.W. Pathophysiology of the brain extracellular matrix: a new target for remyelination. Nat Rev Neurosci 2013, 14:722-729.
35. Worthley D.L., Giraud A.S., Wang T.C. The extracellular matrix in digestive cancer. Cancer Microenviron Off J Int Cancer Microenviron Soc 2010, 3:177-185.
36. He H., Zhang S., Tighe S., Son J., Tseng S.C. Immobilized heavy chain-hyaluronic acid polarizes lipopolysaccharide-activated macrophages toward M2 phenotype. JBiol Chem 2013, 288:25792-25803.
37. Bogie J.F., Jorissen W., Mailleux J., Nijland P.G., Zelcer N., Vanmierlo T., et al. Myelin alters the inflammatory phenotype of macrophages by activating PPARs. Acta Neuropathol Commun 2013, 1:43.
38. Bartus K., James N.D., Didangelos A., Bosch K.D., Verhaagen J., Yanez-Munoz R.J., et al. Large-scale chondroitin sulfate proteoglycan digestion with chondroitinase gene therapy leads to reduced pathology and modulates macrophage phenotype following spinal cord contusion injury. JNeurosci 2014, 34:4822-4836.
39. Freytes D.O., Tullius R.S., Badylak S.F. Effect of storage upon material properties of lyophilized porcine extracellular matrix derived from the urinary bladder. JBiomed Mater Res B Appl Biomater 2006, 78B:327-333.
40. Crapo P.M., Medberry C.J., Reing J.E., Tottey S., van der Merwe Y., Jones K.E., et al. Biologic scaffolds composed of central nervous system extracellular matrix. Biomaterials 2012, 33:3539-3547.
41. Gilbert T.W., Stolz D.B., Biancaniello F., Simmons-Byrd A., Badylak S.F. Production and characterization of ECM powder: implications for tissue engineering applications. Biomaterials 2005, 26:1431-1435.
42. Boltz-Nitulescu G., Wiltschke C., Holzinger C., Fellinger A., Scheiner O., Gessl A., et al. Differentiation of rat bone marrow cells into macrophages under the influence of mouse L929 cell supernatant. JLeukoc Biol 1987, 41:83-91.
43. Stout R.D., Jiang C., Matta B., Tietzel I., Watkins S.K., Suttles J. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. JImmunol 2005, 175:342-349.
44. Munder M., Eichmann K., Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. JImmunol 1998, 160:5347-5354.
45. Albina J.E., Mills C.D., Henry W.L., Caldwell M.D. Temporal expression of different pathways of 1-arginine metabolism in healing wounds. JImmunol 1990, 144:3877-3880.
46. von Zahn J., Möller T., Kettenmann H., Nolte C. Microglial phagocytosis is modulated by pro- and anti-inflammatory cytokines. Neuroreport 1997, 8:3851-3856.
47. Mio K., Carrette O., Maibach H.I., Stern R. Evidence that the serum inhibitor of hyaluronidase may be a member of the inter-α-inhibitor family. JBiol Chem 2000, 275:32413-32421.
48. Sheldon K.E., Shandilya H., Kepka-Lenhart D., Poljakovic M., Ghosh A., Morris S.M. Shaping the murine macrophage phenotype: IL-4 and cyclic AMP synergistically activate the arginase I promoter. JImmunol 2013, 191:2290-2298.
49. Chang C.I., Liao J.C., Kuo L. Arginase modulates nitric oxide production in activated macrophages. Am J Physiol 1998, 274:H342-H348.
50. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010, 11:889-896.
51. Yamaguchi Y. Lecticans: organizers of the brain extracellular matrix. Cell Mol Life Sci 2000, 57:276-289.
52. Wilson C., Leopard J., Cheresh D., Nakamura R. Extracellular matrix and integrin composition of the normal bladder wall. World J Urol 1996, 14:S30-S37.
53. Crapo P.M., Gilbert T.W., Badylak S.F. An overview of tissue and whole organ decellularization processes. Biomaterials 2011, 32:3233-3243.
54. Keane T.J., Londono R., Turner N.J., Badylak S.F. Consequences of ineffective decellularization of biologic scaffolds on the host response. Biomaterials 2011, 33:1771-1781.
55. Wolf M.T., Daly K.A., Reing J.E., Badylak S.F. Biologic scaffold composed of skeletal muscle extracellular matrix. Biomaterials 2012, 33:2916-2925.
56. Keane T.J., Londono R., Carey R.M., Carruthers C.A., Reing J.E., Dearth C.L., et al. Preparation and characterization of a biologic scaffold from esophageal mucosa. Biomaterials 2013, 34:6729-6737.
57. Town T., Nikolic V., Tan J. The microglial "activation" continuum: from innate to adaptive responses. JNeuroinflammation 2005, 2:24.
58. Neher J.J., Neniskyte U., Zhao J.-W., Bal-Price A., Tolkovsky A.M., Brown G.C. Inhibition of microglial phagocytosis is sufficient to prevent inflammatory neuronal death. JImmunol 2011, 186:4973-4983.
59. Aronoff D.M., Canetti C., Peters-Golden M. Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. JImmunol 2004, 173:559-565.
60. Kalinski P. Regulation of immune responses by prostaglandin E2. JImmunol 2012, 188:21-28.
61. Heusinkveld M., de Vos van Steenwijk P.J., Goedemans R., Ramwadhdoebe T.H., Gorter A., Welters M.J.P., et al. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. JImmunol 2011, 187:1157-1165.
62. Stolina M., Sharma S., Lin Y., Dohadwala M., Gardner B., Luo J., et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. JImmunol 2000, 164:361-370.
63. Shen W., Prisk V., Li Y., Foster W., Huard J. Inhibited skeletal muscle healing in cyclooxygenase-2 gene-deficient mice: the role of PGE2 and PGF2α. JAppl Physiol 2006, 101:1215-1221.
64. Casado M., Callejas N.A., Rodrigo J., Zhao X., Dey S.K., Boscá L., et al. Contribution of cyclooxygenase-2 to liver regeneration after partial hepatectomy. FASEB J 2001, 15(11):2016-2018.
65. McCullough L., Wu L., Haughey N., Liang X., Hand T., Wang Q., et al. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. JNeurosci 2004, 24:257-268.
66. Sheibanie A.F., Yen J.H., Khayrullina T., Emig F., Zhang M., Tuma R., et al. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23 IL-17 axis. JImmunol 2007, 178:8138-8147.
67. Lane N.E. Pain management in osteoarthritis: the role of COX-2 inhibitors. JRheumatol Suppl 1997, 49:20-24.
68. Marnett L.J., Kalgutkar A.S. Cyclooxygenase 2 inhibitors: discovery, selectivity and the future. Trends Pharmacol Sci 1999, 20:465-469.
69. Takayama K., García-Cardena G., Sukhova G.K., Comander J., Gimbrone M.A., Libby P. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. JBiol Chem 2002, 277:44147-44154.
70. Betz M., Fox B.S. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. JImmunol 1991, 146:108-113.
71. Demeure C.E., Yang L.-P., Desjardins C., Raynauld P., Delespesse G. Prostaglandin E2 primes naive T cells for the production of anti-inflammatory cytokines. Eur J Immunol 1997, 27:3526-3531.
72. Shen W., Li Y., Tang Y., Cummins J., Huard J. NS-398, a cyclooxygenase-2-specific inhibitor, delays skeletal muscle healing by decreasing regeneration and promoting fibrosis. Am J Pathol 2005, 167:1105-1117.
73. Munder M. Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol 2009, 158:638-651.
74. Modolell M., Corraliza I.M., Link F., Soler G., Eichmann K. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH 1 and TH 2 cytokines. Eur J Immunol 1995, 25:1101-1104.
75. Corraliza I.M., Soler G., Eichmann K., Modolell M. Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bone-marrow-derived macrophages. Biochem Biophys Res Commun 1995, 206:667-673.
76. Menzies F.M., Henriquez F.L., Alexander J., Roberts C.W. Sequential expression of macrophage anti-microbial/inflammatory and wound healing markers following innate, alternative and classical activation. Clin Exp Immunol 2010, 160:369-379.
77. Wang X.-P., Chen Y.-G., Qin W.-D., Zhang W., Wei S.-J., Wang J., et al. Arginase I attenuates inflammatory cytokine secretion induced by lipopolysaccharide in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2011, 31:1853-1860.
78. Campbell L., Saville C.R., Murray P.J., Cruickshank S.M., Hardman M.J. Local arginase 1 activity is required for cutaneous wound healing. JInvest Dermatol 2013, 133:2461-2470.
79. Kavalukas S.L., Uzgare A.R., Bivalacqua T.J., Barbul A. Arginase inhibition promotes wound healing in mice. Surgery 2012, 151:287-295.
80. Campo G.M., Avenoso A., Campo S., D'Ascola A., Nastasi G., Calatroni A. Molecular size hyaluronan differently modulates toll-like receptor-4 in LPS-induced inflammation in mouse chondrocytes. Biochimie 2010, 92:204-215.
81. Neumann A., Schinzel R., Palm D., Riederer P., Münch G. High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-κB activation and cytokine expression. FEBS Lett 1999, 453:283-287.
82. McKee C.M., Penno M.B., Cowman M., Burdick M.D., Strieter R.M., Bao C., et al. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. JClin Investig 1996, 98:2403-2413.
83. Franz S., Allenstein F., Kajahn J., Forstreuter I., Hintze V., Moller S., et al. Artificial extracellular matrices composed of collagen I and high-sulfated hyaluronan promote phenotypic and functional modulation of human pro-inflammatory M1 macrophages. Acta Biomater 2013, 9:5621-5629.
84. Kajahn J., Franz S., Rueckert E., Forstreuter I., Hintze V., Moeller S., et al. Artificial extracellular matrices composed of collagen I and high sulfated hyaluronan modulate monocyte to macrophage differentiation under conditions of sterile inflammation. Biomatter 2012, 2:226-236.